Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 877M 752M 703M 645M 1.21B 83.84B 1.23B 8.29B 3.25B 42.05B 3.29B 3.22B 139B P/E 2026 *
15x
P/E 2027 * 12x
Enterprise Value 877M 752M 703M 645M 1.21B 83.84B 1.23B 8.29B 3.25B 42.05B 3.29B 3.22B 139B EV / Sales 2026 *
2.87x
EV / Sales 2027 * 2.35x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day+7.66%
1 week+12.16%
Current month+27.57%
1 month+15.84%
3 months+65.94%
6 months+28.17%
Current year+9.64%
1 week 40.54
Extreme 40.5433
47.25
1 month 35.01
Extreme 35.0057
47.25
Current year 24.95
Extreme 24.95
49.1
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Free

Chief Technology Officer

24,400 0.1319%
5/15/26 Free

Chairman

5,750 0.0311%
2/20/26 Fiscal year

Director

12,000 0.0661%
Change 5-day change 1-year change 3-year change Capi.($)
+7.66%+12.16%+20.60%+311.93% 815M
+4.46%+4.92%+82.07%+134.31% 1,093B
+0.85%+4.81%+53.77%+58.51% 653B
+2.72%+6.92%+28.99%+77.15% 458B
+1.80%+0.52%+41.20%+44.05% 355B
+1.24%+2.35%+25.99%+42.21% 294B
+2.07%+2.97%+2.27%+13.06% 248B
+4.02%+6.29%+49.67%+68.96% 230B
+1.05%-0.02%-13.96%-52.13% 203B
+2.90%+8.63%+25.11%+94.52% 178B
Average +2.50%+4.03%+31.57%+79.26% 371.13B
Weighted average by Cap. +1.53%+3.65%+46.87%+73.79%

Financials

2026 *2027 *
Net sales 306M 262M 245M 225M 423M 29.22B 429M 2.89B 1.13B 14.66B 1.15B 1.12B 48.46B 373M 320M 299M 274M 515M 35.64B 524M 3.52B 1.38B 17.87B 1.4B 1.37B 59.09B
Net income 61.66M 52.89M 49.39M 45.31M 85.21M 5.89B 86.61M 583M 228M 2.96B 232M 226M 9.77B 81.45M 69.87M 65.24M 59.85M 113M 7.78B 114M 770M 301M 3.9B 306M 299M 12.91B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-08-19 US$46.96 +7.66% 515,733
26-08-18 US$43.62 +2.76% 267,317
26-08-17 US$42.45 -0.31% 502,496
26-08-14 US$42.58 +4.39% 224,043
26-08-13 US$40.79 -2.58% 265,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
46.96USD
Average target price
63.00USD
Spread / Average Target
+34.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock